# Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

> **NCT02921789** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 67 (actual)

## Conditions studied

- Kidney Transplantation
- Primary Focal Segmental Glomerulosclerosis (FSGS)

## Interventions

- **DRUG:** Bleselumab
- **DRUG:** Basiliximab
- **DRUG:** Mycophenolate Mofetil (MMF)
- **DRUG:** Tacrolimus Capsules
- **DRUG:** Methylprednisone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02921789
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-22
- **Primary completion:** 2020-12-11
- **Final completion:** 2021-05-18
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02921789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02921789, "Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02921789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*